Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Crohn's disease

Crohn's disease is an ongoing condition that causes inflammation of the digestive tract, or the GI (gastrointestinal) tract (the gut).

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :"Dr. Arun Bhatt's views and comments".. 2009-09-19 22:03:55 
Sushma Naidu
Newbie
Joined: 2009-07-27 17:07:19
Posts: 15
Location

1.Is IEC Approval required for PMS Studies-(Observational studies) and if yes, is it required from all the sites where the study is taking place.

If it is non-interventional study, EC approval is not required

See the ICMR 2006 guidance

Phase IV studies or post marketing surveillance is undertaken to obtain additional information about the risks and benefits resulting from long term usage of drug. It is an important aspect of drug trial on the long-term effects of the drugs and the adverse reactions induced by drugs, if any, should be brought to the notice of the Ethics Committee.

In addition there are Phase IV studies that are designed to evaluate the marketed drug in specifically designed studies, which have inclusion/exclusion criteria, objectives and end points. The drug is used for the labeled indication in these studies. Therefore Licensing Authority permission is not needed. However, EC permission is needed.

A third type of post-marketing study involves evaluation of the drug for a new indication of a marketed drug, eg. studies with letrazole. Here, DCGI permission and EC approval are needed which really makes the trial a Phase III study.

2.Is Insurance required for PMS Studies as many sponsors say they don't require as the drug is in the market.

Most sponsors have a product liability insurance which covers marketed drugs

3.In Phase 2/3,the clinical report is called as CSR,but what is the term used for preparation of PMS study report.Is it also a CSR or different terminology is used.

CSR includes all phases of development including Phase IV PMS study.


4.If a sponsor wants do a study(PMS) to assess the safety on and efficacy on more patients, is DCGI permission required.


If number is more than DCGI approved, the sponsor needs DCGI permission to include additional patients.

5.In Phase 4 study, if the sponsor has come out with combination drug, then DCGI approval required


Yes if the combination falls in category of new drug as per 122 E.


 

IP Logged
Last Edited On: 2009-09-19 22:03:55 By Sushma Naidu for the Reason
 Subject :Re:"Dr. Arun Bhatt's views and comments".. 2009-09-22 04:59:39 
madhu
Newbie
Joined: 2009-09-21 20:27:43
Posts: 1
Location
can u provide me more information about this
IP Logged
 Subject :Re:"Dr. Arun Bhatt's views and comments".. 2009-10-14 00:47:00 
Sushma Naidu
Newbie
Joined: 2009-07-27 17:07:19
Posts: 15
Location

Hi Madhu,

 

Please tell me where it is not elaborative or informative, then I can explain to you point wise.

Regards,

Sushma

IP Logged
Page # 


Powered by ccBoard